RL
Rhodemann Li
Addressing a $60 Billion/yr problem for Pharma: high failure rates in Ph2, Ph3 trials. We generate proprietary causal and mechanistic insights so Pharma and AI models learn “why” drugs work before committing to trials.
Greater Boston
Founder
Causal Data AI
Aug 2025 - Present
Boston, MA
Founder, EVP Strategy
Vesselon, Inc.
• www.linkedin.com/company/vesselon
Jan 2012 - Sep 2024
CT
Founder of Vesselon
ABCT: Accelerator for Biosciences in Connecticut
• abct.co
Jan 2018 - Sep 2018
Middlebury College
Economics
Jan 1977 - Dec 1981
roger ludlowe high school
Addressing a $60 Billion/yr problem for Pharma: high failure rates in Ph2, Ph3 trials. We generate proprietary causal and mechanistic insights so Pharma and AI models learn “why” drugs work before committing to trials.
Greater Boston